Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have earned a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $11.6667.

ACRV has been the topic of several recent research reports. Weiss Ratings upgraded shares of Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. Jefferies Financial Group restated a “buy” rating on shares of Acrivon Therapeutics in a research report on Monday, March 2nd. Finally, Wall Street Zen lowered shares of Acrivon Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, March 1st.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of institutional investors have recently modified their holdings of ACRV. UBS Group AG boosted its stake in shares of Acrivon Therapeutics by 150,057.8% during the 3rd quarter. UBS Group AG now owns 683,218 shares of the company’s stock valued at $1,237,000 after buying an additional 682,763 shares during the period. Marshall Wace LLP boosted its stake in shares of Acrivon Therapeutics by 231.4% during the 4th quarter. Marshall Wace LLP now owns 496,081 shares of the company’s stock valued at $1,196,000 after buying an additional 346,366 shares during the period. Jane Street Group LLC acquired a new stake in shares of Acrivon Therapeutics during the 2nd quarter valued at $371,000. Two Sigma Investments LP boosted its stake in shares of Acrivon Therapeutics by 76.2% during the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock valued at $578,000 after buying an additional 138,033 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Acrivon Therapeutics by 19.6% in the 1st quarter. Renaissance Technologies LLC now owns 758,440 shares of the company’s stock valued at $1,054,000 after purchasing an additional 124,271 shares during the last quarter. Institutional investors and hedge funds own 71.62% of the company’s stock.

Acrivon Therapeutics Stock Performance

Acrivon Therapeutics stock opened at $1.38 on Thursday. The firm has a market cap of $59.06 million, a price-to-earnings ratio of -0.69 and a beta of 1.89. Acrivon Therapeutics has a 1 year low of $1.15 and a 1 year high of $3.56. The firm’s 50 day moving average price is $1.70 and its two-hundred day moving average price is $1.87.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.49). As a group, equities analysts predict that Acrivon Therapeutics will post -1.92 EPS for the current fiscal year.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.